Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

por Sommer, Eeva M., Dry, Hannah, Cross, Darren, Guichard, Sylvie, Davies, Barry R., Alessi, Dario R.
Publicado 2013

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

por Fox, Emily M, Kuba, María Gabriela, Miller, Todd W, Davies, Barry R, Arteaga, Carlos L
Publicado 2013

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

por De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu
Publicado 2016

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer...

por CRAFTER, CLAIRE, VINCENT, JOHN P., TANG, ERIC, DUDLEY, PHILLIPPA, JAMES, NEIL H., KLINOWSKA, TERESA, DAVIES, BARRY R.
Publicado 2015

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

por Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.
Publicado 2018

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

por Lynch, James T., McEwen, Robert, Crafter, Claire, McDermott, Ultan, Garnett, Mathew J., Barry, Simon T., Davies, Barry R.
Publicado 2016

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

por Feng, Shu, Shao, Longjiang, Castro, Patricia, Coleman, Ilsa, Nelson, Peter S, Smith, Paul D, Davies, Barry R, Ittmann, Michael
Publicado 2016

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia

por Chapman, Elinor A., Oates, Melanie, Mohammad, Ishaque S., Davies, Barry R., Stockman, Paul K., Zhuang, Jianguo, Pettitt, Andrew R.
Publicado 2017

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

por Ezell, Scott A., Wang, Suping, Bihani, Teeru, Lai, Zhongwu, Grosskurth, Shaun E., Tepsuporn, Suprawee, Davies, Barry R., Huszar, Dennis, Byth, Kate F.
Publicado 2016

Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment

por Searle, Emma J, Telfer, Brian A, Mukherjee, Debayan, Forster, Duncan M, Davies, Barry R, Williams, Kaye J, Stratford, Ian J, Illidge, Tim M
Publicado 2017

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

por Butler, Dominika E., Marlein, Christopher, Walker, Hannah F., Frame, Fiona M., Mann, Vincent M., Simms, Matthew S., Davies, Barry R., Collins, Anne T., Maitland, Norman J.
Publicado 2017

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

por O'Neill, Daniel, Jones, Dominic, Wade, Mark, Grey, James, Nakjang, Sirintra, Guo, Wenrui, Cork, David, Davies, Barry R., Wedge, Steve R., Robson, Craig N., Gaughan, Luke
Publicado 2015

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

por Li, Jing, Davies, Barry R, Han, Sufang, Zhou, Minhua, Bai, Yu, Zhang, Jingchuan, Xu, Yan, Tang, Lily, Wang, Huiying, Liu, Yuan Jie, Yin, Xiaolu, Ji, Qunsheng, Yu, De-Hua
Publicado 2013

Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model

por Jiang, Yanyan, Martin, Jennifer, Alkadhimi, Maryam, Shigemori, Kay, Kinchesh, Paul, Gilchrist, Stuart, Kersemans, Veerle, Smart, Sean, Thompson, James M., Hill, Mark A., O’Connor, Mark J., Davies, Barry R., Ryan, Anderson J.
Publicado 2021

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

por Nakamura, Kyoko, Karmokar, Ankur, Farrington, Paul M., James, Neil H., Ramos-Montoya, Antonio, Bickerton, Susan J., Hughes, Gareth D., Illidge, Timothy M., Cadogan, Elaine B., Davies, Barry R., Dovedi, Simon J., Valge-Archer, Viia
Publicado 2021

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

por Dunn, Shanade, Eberlein, Cath, Yu, Jason, Gris-Oliver, Albert, Ong, Swee Hoe, Yelland, Urs, Cureton, Natalie, Staniszewska, Anna, McEwen, Robert, Fox, Millie, Pilling, James, Hopcroft, Philip, Coker, Elizabeth A., Jaaks, Patricia, Garnett, Mathew J., Isherwood, Beverley, Serra, Violeta, Davies, Barry R., Barry, Simon T., Lynch, James T., Yusa, Kosuke
Publicado 2022

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

por Fok, Jacqueline H. L., Ramos-Montoya, Antonio, Vazquez-Chantada, Mercedes, Wijnhoven, Paul W. G., Follia, Valeria, James, Neil, Farrington, Paul M., Karmokar, Ankur, Willis, Sophie E., Cairns, Jonathan, Nikkilä, Jenni, Beattie, David, Lamont, Gillian M., Finlay, M. Raymond V., Wilson, Joanne, Smith, Aaron, O’Connor, Lenka Oplustil, Ling, Stephanie, Fawell, Stephen E., O’Connor, Mark J., Hollingsworth, Simon J., Dean, Emma, Goldberg, Frederick W., Davies, Barry R., Cadogan, Elaine B.
Publicado 2019

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-a...

por Fu, Xiaoyong, Creighton, Chad J, Biswal, Nrusingh C, Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Gladys, Nardone, Agostina, Karlin, Kristen L, Westbrook, Thomas F, Heiser, Laura M, Anur, Pavana, Spellman, Paul, Guichard, Sylvie M, Smith, Paul D, Davies, Barry R, Klinowska, Teresa, Lee, Adrian V, Mills, Gordon B, Rimawi, Mothaffar F, Hilsenbeck, Susan G, Gray, Joe W, Joshi, Amit, Osborne, C Kent, Schiff, Rachel
Publicado 2014

Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy

por Patterson, Claire M., Balachander, Srividya B., Grant, Iain, Pop-Damkov, Petar, Kelly, Brian, McCoull, William, Parker, Jeremy, Giannis, Michael, Hill, Kathryn J., Gibbons, Francis D., Hennessy, Edward J., Kemmitt, Paul, Harmer, Alexander R., Gales, Sonya, Purbrick, Stuart, Redmond, Sean, Skinner, Matthew, Graham, Lorraine, Secrist, J. Paul, Schuller, Alwin G., Wen, Shenghua, Adam, Ammar, Reimer, Corinne, Cidado, Justin, Wild, Martin, Gangl, Eric, Fawell, Stephen E., Saeh, Jamal, Davies, Barry R., Owen, David J., Ashford, Marianne B.
Publicado 2021